Hairy cell leukemia (HCL) is an indolent B-cell malignancy, with long-term responses to
purine analogs, but with decreasing efficacy and increasing toxicity with repeated courses …

Background Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF
V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving …

Background Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin. Here,
we present the long-term follow-up analysis of the pivotal, multicenter, open-label trial …

Hairy cell leukemia variant (HCLv) responds poorly to purine analogue monotherapy.
Rituximab concurrent with cladribine (CDAR) improves response rates, but long-term …

Introduction: Hairy cell leukemia is a rare indolent B-cell malignancy, characterized by
pancytopenia, recurrent infections, and splenomegaly. After initial therapy with purine …

BRAFV600E mutation is the pathogenic driver of hairy cell leukemia (HCL) found in the vast
majority of cases both at onset and during recurrences. The identification of the mutated …

Die Haarzellleukämie (HCL) ist eine seltene chronische B-Zell-Neoplasie, die durch eine
ausgeprägte Splenomegalie, eine progressive Panzytopenie und eine reaktive …

Résumé La leucémie à tricholeucocytes est une hémopathie maligne rare: trois cents
nouveaux cas sont diagnostiqués chaque année en France. Le diagnostic repose sur:(1) …

Hairy cell leukemia (HCL) is a rare chronic lymphoproliferative disorder, with only
approximately 2000 new cases diagnosed in the United States each year. 1 It is now …

Breast cancer is the second leading cause of cancer deaths among women in the United
States, according to the SEER database. It is estimated that 1 in 8 women will be diagnosed …